Facebook
Twitter
LinkedIn
ForwardReview of the Most Important Presentations from the 2019 San Antonio Breast Cancer Symposium
This program will provide a comprehensive review of the most important presentations from the 2019 San Antonio Breast Cancer Symposium.
Presentations will not be printed. A copy of presentation slides can be accessed via UPMC MyCloud. Instructions on how to access program slides will be emailed to the email address that was provided during online registration.
Target Audience
Physicians, researchers, advanced practice providers, nurses, and other health care professionals who work with individuals with breast cancer.
Learning Objectives
Upon completion of this program, attendees will be able to:
- Identify the most up to date findings in breast cancer clinical and translational research.
- Incorporate research findings to appropriately manage patients with breast cancer.
- Demonstrate understanding of the scientific findings in breast cancer research by demonstrating competence in the clinical setting.
Additional Information
| Attachment | Size |
|---|---|
 SABCR handout-2-7-2020 (007) APPROVED.pdf | 221.73 KB |
8:00 am |
Welcome- Shannon Puhalla, MD |
12:10 pm |
Lunch |
8:15 am |
Genomics- Adrian Lee, PhD |
12:30 pm |
Tumor Board (3 cases) moderator: Dhaval Mehta, MD
|
8: 30 am |
Questions & Answers |
1:15 pm |
Breast Imaging Update - Uzma Waheed |
8:35 am |
Immunotherapy Update- Leisha Emens, MD, PhD |
1:35 pm |
Surgery Update – Priscilla McAuliffe, MD, PhD, FACS Mia Diego, MD |
8:55 am |
BRAC related cancer- Shannon Puhalla, MD |
2:00 pm |
Radiation Oncology Update - John Austin Vargo, MD |
9:10 am |
Questions & Answers |
2:20 pm |
Questions & Answers |
9:20 am |
Keynote Speaker- Norman Wolmark - NSABP, past, present, and future |
2:30 pm |
Keep in Mind Studies- Terry Evans, MD, FACP |
10:00 am |
Questions & Answers |
2:50 pm |
Survivorship – Josie van Londen, MD, MSc |
10:10 am | Break |
3:05 |
Questions & Answers/ Departing Comments |
10:30 am |
HER2 Metastatic Update- Adam Brufsky, MD, PhD, FACP | 3:30 pm | Adjournment |
COURSE DIRECTORS:
Dhaval Mehta, MD
Clinical Assistant Professor
University of Pittsburgh School of Medicine
UPMC Hillman Cancer Center, Monroeville
Shannon Puhalla, MD
Assistant Professor of Medicine
University of Pittsburgh School of Medicine
UPMC Hillman Cancer Center
UPMC Passavant
Magee-Women's Hospital of UPMC
Adam Brufsky, MD, PhD, FACP Professor of Medicine University of Pittsburgh School of Medicine Associate Division Chief Division of Hematology/Oncology University of Pittsburgh School of Medicine Medical Director, Magee Women’s Cancer Program UPMC Hillman Cancer Center Associate Director for Clinical Investigations UPMC Hillman Cancer Center Co-Director, Comprehensive Breast Cancer Center Magee-Women's Hospital of UPMC
Emilia Diego, MD Assistant Professor University of Pittsburgh School of Medicine Magee-Women's Hospital of UPMC
Leisha A. Emens, MD PhD Professor of Medicine UPMC Hillman Cancer Center/Magee Women's Hospital Director of Translational Immunotherapy for the Women's Cancer Research Center Co-Leader, Hillman Cancer Immunology/Immunotherapy Program
Terry L. Evans, MD, FACP Clinical Assistant Professor of Medicine, University of Pittsburgh School of Medicine Medical Director of the Arnold Palmer Cancer Center.
Vikram Gorantla, MD Medical Oncologist UPMC Hillman Cancer Center
Adrian V. Lee, PhD Pittsburgh Foundation Endowed Chair in Precision Medicine Professor of Pharmacology & Chemical Biology Director, Institute for Precision Medicine UPMC Hillman Cancer Center
Priscilla McAuliffe, MD, PhD, FACS Assistant Professor of Surgery University of Pittsburgh School of Medicine Magee-Women's Hospital of UPMC
| M. Pervaiz Rahman, MD Clinical Assistant Professor University Pittsburgh School of Medicine UPMC Hillman Cancer Center
Priya Rastogi, MD Senior Associate Medical Director NSABP Medical Affairs Associate Professor of Medicine University of Pittsburgh School of Medicine UPMC Hillman Cancer Center
G. van Londen, MD, MSc Director, Cancer LiveWell Survivorship Program UPMC Hillman Cancer Center Magee-Women's Cancer Program Rohit Bhargava, M.D. Professor of Pathology, University of Pittsburgh Interim Chief of Pathology, Magee-Women's Hospital of UPMC
John Austin Vargo, MD Assistant Professor of Radiation Oncology Regional Medical Director, Central Region Magee Women's Hospital of UPMC
Uzma Waheed Assistant Professor, Department of radiology University of Pittsburgh school of Medicine Magee women’s hospital of UPMC
Norman Wolmark, MD Chairman, NSABP Group Chair and Contact PI, NRG Oncology Professor of Surgery, University of Pittsburgh
|
All individuals in a position to control the content of this education activity including members of the planning committee, speakers, presenters, authors, and/or content reviewers have disclosed all relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients.
The following relevant financial relationships were disclosed:
- Adam Brufsky, MD, PhD, MD – Consultant: Puma, Seattle Genetics, Daiichi, Roche, AstraZeneca
- Adrian V. Lee, PhD – Grant/Research: NIH/NCI, Susan G. Komen, BCRF, PA DOH, Glimmer of Hope, Ocean Genomics; Consultant: Enterprises, Boehringer Ingelheim; Stockholder: Ocean Genomics
- John Austin Vargo, MD – Other: Clinical Pathways, Elselvier
- Leisha A. Emens, MD, PhD – Consult Board/Advisory: AbbVie, Amgen, AstraZeneca, Bayer, Bristol Meyers Squibb, Celgene, Chugai, eTheRNA, Genentech, Gritstone, Medimmune, Molecuvax, Marcrogenics, Novartis, Peregrine, Replimune, Roche, Silverback, Syndax, Vaccine; Research Funding: Aduro Biotech, AstraZeneca, Breast Cancer research Foundation, Bristol Meyer Squibb, Corvus, Department of defense EMD Serono, Genentech, HertiX, Inc., Maxcyte, Merck, National Cancer Institute, NSABP Foundation, Roche, Tempest, Translational Breast cancer Research Consortium, Royalty: Aduro IND Licensing/vaccine
EMD Serono, Genentech, HertiX, Inc., Maxcyte, Merck, National Cancer Institute, NSABP Foundation, Roche, Tempest, Translational Breast cancer Research Consortium, Royalty: Aduro IND Licensing/vaccine
- Shannon Puhalla, MD – Grant/Research: AbbVie, Pfizer, Lilly, Novartis, Incyte, Covariance-Bayer, AstraZeneca, Consultant: AbbVie, MedImmune, Celldex, Puma, Pfizer, AstraZeneca, Esai, nanostring
- Uzma Waheed, MD – Consultant: Becton Dickinson
- Priya Rastogi, MD – Other, travel and Accommodations: Lilly/Genentech, AstraZeneca
- Vikram Gorantla, MD – Consultant: Mylan, IntegraConnect
No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose. Acknowledgement of Commercial Support: Utilize the following statement whenever commercial support has been obtained for this activity. You may only list a company if a signed letter of agreement and the check have been received.
Accreditation and credit designation
Physicians
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Pittsburgh School of Medicine designates this live activity for a maximum of 6.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.
Available Credit
- 6.75 AMA PRA Category 1 Credit™The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
- 6.75 Attendance